Metastatic Urothelial Carcinoma: Unmet Needs and Future Directions
Expert reflection on the current unmet needs in metastatic urothelial carcinoma and hope for future improvements in the treatment armamentarium.
Treatment Options After Frontline Maintenance Therapy in mUC
Following frontline maintenance therapy in metastatic urothelial carcinoma, Ignacio Duran, MD, PhD, considers optimal second-line treatment options.
Metastatic Urothelial Carcinoma: Optimizing Use of Frontline Maintenance Therapy
Shared insight on the use of maintenance therapy in metastatic urothelial carcinoma with regard to PD-L1 testing and patient education.
Interpreting JAVELIN Bladder 100: Avelumab in Metastatic Urothelial Carcinoma
Ignacio Duran, MD, PhD, reflects on the JAVELIN Bladder 100 trial, which analyzed avelumab as frontline maintenance therapy in metastatic urothelial carcinoma.
Immunotherapy’s Roles in Treating Metastatic Urothelial Carcinoma
Considerations for the role of immunotherapy in metastatic urothelial carcinoma as maintenance or switch therapy.
A Global View on Metastatic Urothelial Carcinoma
Expert perspective on the current treatment paradigm of metastatic urothelial carcinoma across different regions of the world.
Lung Responses to Atezolizumab/Bevacizumab Linked With OS in HCC and Pulmonary Metastasis
Second-Line Regorafenib Demonstrates Safety in Advanced HCC, Irrespective of Prior Treatment
First-line Toripalimab Plus Sorafenib Elicits Responses in Unresectable Hepatocellular Carcinoma
Data for Luspatercept Highlight Evolving Treatment Landscape in Lower-Risk MDS
2 Clarke Drive Cranbury, NJ 08512